Japanese Journal of Clinical Oncology Advance Access published online on October 26, 2007
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hym098
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 Foundation for Promotion of Cancer Research
Current Status of Endocrine Therapy for Prostate Cancer in Japan—Analysis of Primary Androgen Deprivation Therapy on the Basis of Data Collected by J-CaP
1 Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba
2 Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka
3 Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto
4 Tokushima University Hospital, Tokushima
5 Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo
6 Department of Urology, Sapporo Medical University, School of Medicine, Sapporo
7 Department of Urology, Graduate School of Medical Sciences, Kyushu University, Kyushu
8 Department of Urology, Kanazawa University, School of Medicine, Kanazawa
9 Department of Urology, Nara Medical University, Nara
10 Department of Urology, School of Medicine, Keio University, Tokyo
11 Institute for Preventive Medicine, Kurosawa Hospital, Kurosawa
For reprints and all correspondence: Hideyuki Akaza, Urology and Andrology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba City, Ibaraki prefecture, 305-8575, Japan, E-mail: akazah{at}md.tsukuba.ac.jp
Received February 13, 2007; accepted June 8, 2007
Background: Based on the data of current status of endocrine therapy for prostate cancer registered in the Japan Study Group of Prostate Cancer (J-CaP), we conducted an analysis of primary androgen deprivation therapy (PADT) and an interim analysis of the prognosis.
Methods: Of the 26 272 cases registered in the server of J-CaP, the 19 409 cases initially receiving PADT were included in this study. The initial therapy was divided into eight categories according to its features.
Results: Of the 19 409 patients, 1513 (7.8%) were given anti-androgen monotherapy, 955 patients (4.9%) surgical castration only, 1001 patients (5.2%) surgical castration + anti-androgen, 3015 patients (15.5%) LHRH monotherapy, 1658 patients (8.5%) LH-RH + short-term anti-androgen, 10 434 patients (53.8%) LH-RH + anti-androgen, 37 patients (0.2%) watchful waiting and 796 patients (4.1%) other therapy. In progression-free survival, the prognosis was slightly better following maximum androgen blockade (MAB) in each stage.
Conclusions: The pattern of PADT is more typical in Japan compared with that in the United States. Patients who received MAB accounted for 59.0% of all the patients. MAB tends to be more often selected for patients who are rated as being at high risk on the basis of high Gleason score or PSA level upon diagnosis in each clinical stage of the disease. Investigations of the outcome are on-going and they will make clear the significance of this trend in Japan.
Key Words: primary androgen deprivation therapy • prostate cancer • J-CaP
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. R. Cooperberg, S. Hinotsu, M. Namiki, K. Ito, J. Broering, P. R. Carroll, and H. Akaza Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy J. Clin. Oncol., September 10, 2009; 27(26): 4306 - 4313. [Abstract] [Full Text] [PDF]
|
|